 | This articlerelies excessively onreferences toprimary sources. Please improve this article by addingsecondary or tertiary sources. Find sources: "Charles Swanton" – news ·newspapers ·books ·scholar ·JSTOR(June 2024) (Learn how and when to remove this message) |
Charles Swanton | |
|---|---|
 Swanton in 2018 | |
| Born | Robert Charles Swanton 1972 (age 52–53)[2] |
| Education | St Paul's School, London |
| Alma mater | University College London (MD, PhD) |
| Awards | Ellison–Cliffe Lecture (2017) EMBO Member (2017) |
| Scientific career | |
| Fields | Cancer evolution[1] |
| Institutions | Francis Crick Institute University College London |
| Thesis | Viral cyclin disruption of mammalian cell cycle control mechanisms (1998) |
| Doctoral advisor | Nic Jones |
| Website | www |
Robert Charles Swanton is a Britishphysician scientist specialising inoncology andcancer research. Swanton is a senior group leader at London'sFrancis Crick Institute,[3] Royal Society Napier Professor in Cancer[4] and thoracic medical oncologist atUniversity College London[5] and University College London Hospitals,[6][7] co-director of theCancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.[8][9]
![[icon]](/mt/?noimg=&dark=on&url=https%3a%2f%2fen.wikipedia.org%2fwiki%2fFile%3aWiki_letter_w_cropped.svg) | This sectionneeds expansion. You can help byadding to it.(June 2024) |
Swanton was born inPoole, Dorset. As of 2017, his father Robert Howard Swanton (MD, FRCP) was aconsultant cardiologist at UCL.[10]
Swanton was educated atSt Paul's School, London[2] and completed his PhD in 1999[11] at what was then theImperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008.[7]
Swanton has combined[when?] his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time.[7] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.[1][7][12][13]
As of 2018, Swanton has been a co-founder of Achilles Therapeutics[14] with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute[15] biotechnology company funded bySyncona[16] that develops adoptiveT cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.[citation needed]
| This sectionneeds expansion. You can help byadding to it.(June 2024) |
"All text published under the heading 'Biography' on Fellow profile pages is available underCreative Commons Attribution 4.0 International License." --"Terms, conditions and policies | Royal Society". Archived from the original on 11 November 2016. Retrieved27 June 2018.
{{cite web}}: CS1 maint: bot: original URL status unknown (link)
This article incorporatestext available under theCC BY 4.0 license.
| International | |
|---|---|
| National | |
| Academics | |